Momentum Is Strong For Immuneering Corp (NASDAQ: IMRX)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Immuneering Corp is $84.62M. A total of 0.95 million shares were traded on the day, compared to an average of 538.74K shares.

In the most recent transaction, Feinberg Peter bought 25,000 shares of IMRX for 2.55 per share on Mar 22 ’24. After the transaction, the Director now owns 111,766 company shares. In a previous transaction on Mar 22 ’24, Brakewood Harold Eugene bought 3,900 shares at 2.57 per share. IMRX shares that Chief Business Officer owns now total 3,900.

Among the insiders who bought shares, Schall Thomas J. acquired of 2,900 shares on Mar 22 ’24 at a per-share price of $2.55. This resulted in the Director holding 2,900 shares of IMRX after the transaction. In another insider transaction, Morales Mallory bought 393 shares at $2.55 per share on Mar 22 ’24. Company shares held by the Chief Accounting Officer now total 8,278.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, IMRX has a high of $14.29 and a low of $1.90.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. IMRX’s latest balance sheet shows that the firm has $149.20M in Cash & Short Term Investments as of fiscal 2021. There were $5.36M in debt and $5.63M in liabilities at the time. Its Book Value Per Share was $3.09, while its Total Shareholder’s Equity was $155.98M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMRX is Buy with a score of 4.00.

Most Popular

Related Posts